Sanofi eyes more M&A as deals drive increase in IP portfolio quality
The French pharmaceutical’s holdings have shrunk over recent years and application output is at a low, but recent acquisitions have provided a boost while a patent revamp is around the corner
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.